Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors

J. Kopecky, O. Kubecek, T. Buchler, B. Melichar, A. Poprach, M. Zemanova, J. Katolicka, I. Kiss, J. Hajek, H. Studentova, M. Spisarova

. 2021 ; 35 (5) : 2981-2990. [pub] -

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025023

BACKGROUND/AIM: Immunotherapy with checkpoint inhibitors is currently considered a cornerstone of metastatic renal clear cell cancer (mRCC) therapy. Despite the general improvement in the survival of patients with mRCC, there are some clinical situations that have not been specifically evaluated in clinical trials, such as the use of everolimus before nivolumab. PATIENTS AND METHODS: We performed a retrospective analysis evaluating the efficacy of nivolumab in the real-world setting, including a subset of patients with previous mTOR inhibitor therapy. RESULTS: From a total of 56 patients, 25 were pre-treated with everolimus before receiving nivolumab. The overall progression-free survival (PFS), overall survival (OS), and objective response rate were 10.3, 21.3 months, and 34%, respectively. There were no statistically significant differences in patients who were or were not pre-treated with everolimus. CONCLUSION: mRCC patients should be treated with checkpoint inhibitors and prior use of mTOR inhibitors should not be a definitive exclusion criterium.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025023
003      
CZ-PrNML
005      
20211026134208.0
007      
ta
008      
211013s2021 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/invivo.12593 $2 doi
035    __
$a (PubMed)34410998
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Kopecky, Jindrich $u Department of Oncology and Radiotherapy Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic; jindrich.kopecky@fnhk.cz
245    10
$a Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors / $c J. Kopecky, O. Kubecek, T. Buchler, B. Melichar, A. Poprach, M. Zemanova, J. Katolicka, I. Kiss, J. Hajek, H. Studentova, M. Spisarova
520    9_
$a BACKGROUND/AIM: Immunotherapy with checkpoint inhibitors is currently considered a cornerstone of metastatic renal clear cell cancer (mRCC) therapy. Despite the general improvement in the survival of patients with mRCC, there are some clinical situations that have not been specifically evaluated in clinical trials, such as the use of everolimus before nivolumab. PATIENTS AND METHODS: We performed a retrospective analysis evaluating the efficacy of nivolumab in the real-world setting, including a subset of patients with previous mTOR inhibitor therapy. RESULTS: From a total of 56 patients, 25 were pre-treated with everolimus before receiving nivolumab. The overall progression-free survival (PFS), overall survival (OS), and objective response rate were 10.3, 21.3 months, and 34%, respectively. There were no statistically significant differences in patients who were or were not pre-treated with everolimus. CONCLUSION: mRCC patients should be treated with checkpoint inhibitors and prior use of mTOR inhibitors should not be a definitive exclusion criterium.
650    12
$a karcinom z renálních buněk $x farmakoterapie $7 D002292
650    _2
$a lidé $7 D006801
650    12
$a nádory ledvin $x farmakoterapie $7 D007680
650    _2
$a nivolumab $7 D000077594
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a TOR serin-threoninkinasy $7 D058570
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kubecek, Ondrej $u Department of Oncology and Radiotherapy Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic
700    1_
$a Melichar, Bohuslav $u Department of Oncology and Radiotherapy Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic
700    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Zemanova, Milada $u Department of Oncology, First Faculty of Medicine Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Katolicka, Jana $u Department of Oncology, St. Anne's University Hospital Brno, Brno, Czech Republic
700    1_
$a Kiss, Igor $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Hajek, Jaroslav $u Department of Oncology, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Studentova, Hana $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic
700    1_
$a Spisarova, Martina $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic
773    0_
$w MED00175831 $t In vivo (Athens, Greece) $x 1791-7549 $g Roč. 35, č. 5 (2021), s. 2981-2990
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34410998 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026134214 $b ABA008
999    __
$a ok $b bmc $g 1714188 $s 1145530
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 35 $c 5 $d 2981-2990 $e - $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace